The fall pharma conferences of 2026 mark the season when the industry reconvenes after the summer congresses to turn the year’s science into commercial and operational decisions. [Read more…]
Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models
Landmark data positions ERNA-101 as a potential game-changing immunotherapy and a major catalyst for future clinical and shareholder value
CAMBRIDGE, Mass., May 06, 2026 — Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced new preclinical data demonstrating that its lead cell therapy candidate, ERNA-101, in combination with PD-1 blockade, drives complete tumor clearance and 100% long-term survival in syngeneic ovarian cancer models. [Read more…]
FUJIFILM Biosciences and NextCell Launch New Commercial Platform Comprised of RUO Stromal Cells and Cell Culture Media
-
Collaboration results in platform to help researchers overcome challenges in MSC research
-
NextCell-Cord RUO cells designed for delivery as cryopreserved and sold as an individual product or bundled with PRIME-XV media from FUJIFILM Biosciences
SANTA ANA, Calif., USA and HUDDINGE, SWEDENÂ – FUJIFILM Biosciences, a global leader in the life science market, and NextCell Pharma AB, a clinical-stage company specializing in cell therapy using umbilical cord mesenchymal stromal cells (MSC), today announced a global commercial launch resulting from their strategic collaboration. The offering consists of FUJIFILM Biosciences’Â PRIME-XV MSC Expansion XSFMÂ medium and NextCell’s first commercial product, NextCell-Cord RUO, a research-use-only (RUO) MSC product derived from umbilical cord tissue. [Read more…]
UCB’s $1.15 Billion Bet on Neurona Signals Major Push into Pluripotent Stem Cell–Derived Cell Therapy
In one of the largest regenerative medicine deals of 2026 to date, UCB has announced plans to acquire Neurona Therapeutics in a transaction valued at an astounding price tag: up to $1.15 billion. The deal includes $650 million upfront, with an additional $500 million tied to future milestones, underscoring the scale of UCB’s commitment to next-generation therapeutic modalities. [Read more…]
The Top Life Science & Biotech Conferences to Attend in the U.S. in 2026
The 2026 biotech conferences calendar is one of the densest years biopharma and the broader life sciences industry have seen.
FDA approval velocity remains high. Inflation Reduction Act implementation is entering a more consequential phase. Generative AI is moving from R&D experimentation into operational deployment. And biotech investment trends point to a re-opening capital environment after a multi-year reset.
All of that translates into a packed year of events competing for commercial, R&D, investor, and executive attention. [Read more…]
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 62
- Next Page »